Last month, the Institute for Clinical and Economic Review (ICER) issued a draft report on the cost-effectiveness of bluebird bio’s lovo-cel (lovotibeglogene autotemcel) and Vertex/CRISPR’s ...
This study examines the availability of cost-effectiveness analyses for medical devices, both in terms of the number of studies and when studies are published. Objectives: Academic researchers and ...
Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results